1Pharmaceutics, Kavayitri Bahinabai Chaudhari NMU University, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
2Pharmaceutical Quality Assurance, Kavayitri Bahinabai Chaudhari NMU University, P.S.G.V.P. Mandal’s College of Pharmacy, Shahada, Maharashtra, India
3Pharmaceutics, Dr. Babasaheb Ambedkar Technological University, Ahinsa Institute of Pharmacy, Dondaicha, Maharashtra, India
*Corresponding Author E-mail: bhupendramahale999@gmail.com
Online published on 27 May, 2025.
The synthetic oestrogen receptor-related orphan receptor (ERR) agonist SLU-PP-332 exhibits promising potential in revolutionizing fitness and weight loss strategies. Through its activation of ERRs, SLU-PP-332 enhances energy expenditure, increases fatty acid oxidation, and reduces fat mass buildup. Studies indicate its ability to mimic exercise-induced metabolic pathways, resulting in improved endurance and weight loss in mice. While long-term implications are yet to be fully understood, initial trials show no significant adverse effects. SLU-PP-332 targets ERRs found in various human organs, influencing vital metabolic processes. With implications for treating metabolic disorders like obesity, type 2 diabetes, and heart failure, SLU-PP-332 emerges as a novel therapeutic agent. Its biological activity, structure, and solubility data support its potential as a small molecule drug in endocrinology and metabolic diseases. Further research is warranted to elucidate its long-term effects and refine its structure for future clinical applications.
SLU-PP-332, ERR agonist, Skeletal muscle, Metabolic disorders, Exercise endurance, Therapeutic potential
